Determination 2

Determination 2 - Isatuximab, Iberdomide, Bortezomib and Dexamethasone Induction, Followed by Risk- and Response-Adapted Consolidation and Maintenance Therapy, in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma

More Information

Trial Status
Not yet accepting
Trial Phase
Phase 3
Enrollment
720 patients (estimated)
Tags
Monoclonal Antibody, CD38, Randomization, Maintenance
Trial Type
Treatment
Last Update
SparkCures ID
2263
NCT Identifier
NCT07624513

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.